Low-dose-rate brachytherapy and long-term treatment outcomes in patients younger than 60 years of age

• Published in: Journal of contemporary brachytherapy 2024-02, Vol.16 (1), p.6-11
• Main Authors: Armstrong, Alexander, Ho, Huong, Mark Tacey, MBiostat, Bolton, Damien, Chan, Yee, Tan, Alwin, Cham, Chee Wee, Pham, Trung, McMillan, Kevin, Koufogiannis, George, Dip, Grad, Manohar, Paul, Guerrieri, Mario, Ng, Michael, Joon, Daryl Lim, Foroudi, Farshad, Tan, Mun Yee, Chao, Michael
• Format: Article
• Language: English
• Subjects: brachytherapy; long-term treatment outcomes; low-dose-rate; Original Paper; prostate cancer; toxicity
• ISSN: 1689-832X; 2081-2841
• DOI: 10.5114/jcb.2024.135630

Low-dose-rate (LDR) brachytherapy in young men remains controversial amongst urologists due to their concerns regarding long-term biochemical control and treatment-related toxicities. The purpose of this study was to evaluate the treatment outcomes of men under 60 years of age who underwent LDR brachytherapy with iodine-125 ( I) for clinically localized low- to intermediate-risk prostate cancer. All consecutive patients with clinically localized prostate cancer treated at our institution from 2003 to 2016 with I monotherapy were included in the study. Prescription dose was 145.0 Gy modified peripheral loading (MPD). All patients were assessed for biochemical progression-free survival using Phoenix definition (nadir +2 ng/ml), clinical progression-free survival, overall survival (OS), and any associated treatment toxicity. A total of 161 patients were included, with a median follow-up of 6.8 years (range, 3-14.54 years). Median age at implant was 57 years (range, 53-59 years). Mean prostate specific antigen (PSA) level at diagnosis was 4.43 ng/ml (SD = 2.29). Majority of men had low-risk prostate cancer (70.2%). Biochemical progression-free survival at 8 years was 94% for the entire cohort. Median PSA at 4 years was 0.169 (IQR, 0.096-0.360), with 45% of patients having a PSA greater than 0.2. OS was 96.9%, with 5 deaths reported but only one was secondary to prostate cancer. Late grade > 2 genitourinary toxicities were reported in 18 patients (11.2%). Three patients (1.9%) developed secondary cancers, all considered unrelated to their LDR brachytherapy. With excellent long-term treatment outcomes and minimal associated toxicities, our results showed that LDR brachytherapy can be an effective treatment of choice in younger men.